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worsens over time but does not extend to additional areas of
cognition.
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Introduction
Multisystem involvement in myotonic dystrophies includes
the brain [1, 2]. Neuropsychological tests [3–9], neuropsy-
chiatric interviews [10], neuroimaging [11, 12], neu-
ropathology [13–16] and biomolecular studies [17, 18] all
support this statement. More specifically, there is growing
evidence that cognitive impairment in adult myotonic dys-
trophies is characterised by an impairment in frontal lobe
functions resulting in a dysexecutive syndrome [19], both
in myotonic dystrophy type 1 (DM1) and in myotonic dys-
trophy type 2 (DM2), which is not correlated to the degree
of cortical atrophy or white matter hyperintense lesions on
brain MRI but rather to a reduced cerebral perfusion in the
frontal and temporal lobes by H2O PET scans [20]. Despite
the growing body of evidence of cognitive involvement in
these disorders [21–24], what is less clear is the clinical rel-
evance of these abnormal findings, including neuropsycho-
logical test scores, white matter hyperintense lesions, corti-
cal atrophy [3–9, 25, 26], neurofibrillary tangles, the char-
acteristic tau protein pattern [14–16] or the toxicity of
abnormal ribonuclear inclusions found in specific brain
regions of these patients [17]. Whether these brain abnor-
malities culminate in a dementia syndrome is yet to be
determined. The crucial point here is to determine whether
brain involvement in adult myotonic dystrophies progress-
es over time. Whereas several reports describe follow-up
studies of muscle strength deterioration [27] or progression
of cardiac conduction arrhythmias [28], there are limited
studies on the progression of cognitive decline [29, 30].
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Abstract The clinical relevance and extent of cognitive
impairment in adult myotonic dystrophy type 1 (DM1) and
2 (DM2) is still unclear. The aim of this study was to deter-
mine whether previously reported cognitive abnormalities
progress over time and if this occurs in DM2 as it does in
DM1. Fifty-six patients with DM1 and 29 patients with
DM2 were subjected to muscle strength assessment, and to
a complete battery of neuropsychological tests. Repeated
assessment was performed in 20 DM1 and 13 DM2 over
time (DM1 mean follow-up: 7.3±2.7 years; DM2 mean fol-
low-up: 9.5±2.4 years). Muscle strength and test scores for
frontal lobe functions worsened significantly over time
(p<0.01), in both DM1 and DM2. DM2 is a progressive
muscle disorder, although less severe than DM1. In both
DM1 and DM2 frontal cognitive impairment (attentional)
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In this study we wish to determine whether previously
reported visual-spatial impairment and dysexecutive frontal
lobe syndrome progress over time in DM1 and DM2 and
whether patients develop dementia. We also wish to deter-
mine whether there is a distinct rate of progression between
patients with DM1 compared to DM2.
Materials and methods
Patient selection
Sixty-seven patients with genetically determined DM1 and 34
patients with genetically determined DM2 referred to the
Neuromuscular Clinic of the University of Milan at the IRCCS
Policlinico San Donato were considered in the initial study popu-
lation. Congenital and juvenile myotonic dystrophy patients;
patients with a positive medical history of stroke, diabetes,
dementia, mental retardation, head trauma, alcohol or drug abuse;
patients with MMSE scores below 24 and with a positive Epworth
Sleep Scale (score ≥9); and patients with finger flexor strength
weaker than 3+ were excluded from the study. The selected sam-
ple at the beginning of the study resulted in 56 patients with CTG
expansion ranging between 500 and 700 repeats and 29 patients
with CCTG expansion in the ZNF9 gene. All patients were ambu-
latory. Activity of daily living disability was defined as needing
help in at least one of the following: walking across a small room,
taking a shower, toileting, using the toilet, dressing and eating.
It was possible to administer the neuropsychological tests in
20 of 56 patients with DM1 and 13 of 29 patients with DM2 at the
beginning of the study and in 14 of 20 patients with DM1 and 11
of 13 patients with DM2 on follow-up. A high proportion of
patients included in the initial assessment (36 DM1=64% and 16
DM2=55%) refused neuropsychological follow-up because they
claimed good cognitive performance (refusals, n=22 DM1 and 9
DM2); they died (5 DM1 patients, 2 due to cardiac arrest, 3 to res-
piratory insufficiency; 1 patient with DM2 due to cardiac arrest);
they never returned to the Neuromuscular Clinic, for unknown
reasons (unreachable, 7 DM1 and 5 DM2 patients); or they devel-
oped long finger flexor weakness below 3+ MRC range (2 DM1
and 1 DM2 patients) and were thus excluded from the study.
Patients were subjected to follow-up assessments without any
a priori scheduling, according to the patients’ availability and not
on the basis of subjective neuropsychological worsening. In any
case, the mean follow-up period was considered sufficient to
detect both neuromuscular and neuropsychological potential pro-
gression of disease.
Muscle strength assessment
Muscle strength assessment was determined in all patients in the
initial (56 DM1 and 29 DM2) and follow-up (20 DM1 and 13
DM2) study population. Assessment was made using the modified
5-point MRC scale (Medical Research Council, Aids to the exam-
ination of the peripheral nervous system, Memorandum 45. 1976,
Pendragon House, London) testing 15 muscles on the right and
left and considering a total score (Megascore) of 150 for normal
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muscle strength. All patients with long finger flexor weakness
scoring less than 3+ MRC were excluded to make sure that distal
muscle weakness did not impair performance in those neuropsy-
chological tests requiring visual scanning associated with motor
speed and agility (Divided Attention Test, Alertness and Trail
Making Test). This criterion was applied at initial and at follow-
up assessment to avoid bias due to potential worsening of muscle
dexterity over time. To make sure that motor dexterity would not
influence time-related scores alertness in attentional tasks, perfor-
mance was calculated in trial making test (TMT) B-A, in addition
to TMT A and B considered separately. TMT B-A reflects only
cognitive resource employment because it is calculated subtract-
ing the TMT A score (pure attentional task) from the TMT B score
(visuo-spatial planning).
The same neurologists (VS and GM) evaluated muscle
strength on initial and follow-up assessments. Repeated muscle
strength testing and neuropsychological assessment were per-
formed 2–10 years after initial assessment (mean 7.3±2.7 for
DM1 and 9.5±2.4 for DM2) (Fig. 1).
Neuropsychological assessment
The neuropsychological test battery administered was the one pre-
viously described [19, 20]. It included a screening test for demen-
tia (Mini-Mental State Examination, MMSE) and tests of nonver-
bal reasoning (Raven’s Progressive Colored matrices, RPM),
auditory language comprehension (Token test), verbal fluency
with phonemic and semantic cues, verbal and spatial short-term
memory (Digit Span forward and Spatial Span), verbal and spatial
long-term memory (Story Recall and Rey Recall), constructional
abilities (Rey’s complex copy) , and attention and executive func-
tion (Trail Making A and B, Alertness and Divided Attention
(TEA) and Tower of London Test (TLT)) [31]. The tests were
administered by an experienced examiner in a quiet environment
at the hospital site. Approximately 60–90 min were needed to
administer the battery of tests required. Thirty-seven patients with
DM1 and 17 patients with DM2 were subjected to the complete
battery of neuropsychological tests on initial assessment. Follow-
up was possible in 14 patients with DM1 and 11 patients with
DM2.
The same neuropsychologist (MC) performed the tests on ini-
tial and final assessment.
Data analysis
In order to compare clinical and demographic characteristics at
baseline between DM1 and DM2 patients we performed a
Mann–Whitney U-test.
Non parametric intra-group comparisons for initial assess-
ment were performed using the Mann–Whitney U-test for each
variable considered (muscle strength and neuropsychological per-
formances).
To assess follow-up evolution, nonparametric intra-group
comparisons were employed (Wilcoxon test) for each variable
considered.
ANCOVA adjusted for age, disease duration and follow-up
years was used to assess differences between groups at initial
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assessment for muscle strength, in order to take into account the
influence of these covariates.
Results are expressed as means and standard deviations, if not
otherwise indicated. Significance was set when p<0.05.
Results
Results are expressed as means and standard deviations.
Significance was set when p<0.05.
Table 1 indicates clinical characteristics, muscle
strength and cognitive results in the initial study popula-
tion. Figure 2 indicates initial and follow-up muscle
strength assessment. Tables 2 and 3 indicate neuropsycho-
logical test results in the follow-up population.
No difference for disease duration and age between
groups was found (for details see Table 1). No difference in
activities of daily living (ADL) scores was observed over
time. Patients were totally independent at baseline and
remained totally independent at follow-up.
Muscle strength
Initial assessment
ANCOVA adjusted for age and mean disease duration did
not show any significant difference (p>0.05) between the
two groups (56 DM1 and 29 DM2) for muscle strength
(Table 1).
Follow-up assessment (20 DM1 and 13 DM2)
Mean muscle strength in DM1 (MMRC) decreased signifi-
cantly from 134.5 (±9.0) on initial examination to 124.6
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INITIAL DM POPULATION
EXCLUDED: n=(11 DM1; 5 DM2)
LOST: n=36 DM1 (64%); 16 DM2 (55%)
Refusals n= 22 DM1; 9 DM2
Deaths n=5 DM1 (3 RI; 2 CF); 1 DM2 (CF)
Unreachable n=7 DM1; 5 DM2
FF MRC >3+ n=2 DM1; 1 DM2
STUDY SAMPLE
FINAL FOLLOW-UP
POPULATION
DM1
n=67
DM1
n=56
DM1
n=20
(36%)
DM2
n=13
(45%)
DM2
n=34
DM2
n=29
Fig. 1 Diagram illustrating initial and follow-up
DM1 and DM2 study population. CF, cardiac fail-
ure; RI, respiratory insufficiency
Table 1 Clinical, neuromuscular and general intelligence profiles of 56 patients with DM1 (23 women and 33 men) and 29 patients with
DM2 (15 women and 14 men) subjected to muscle strength assessment and neuropsychological tests on initial assessment
DM1 (n=56) DM2 (n=29) p
Age 44.9±14.8 55.1±12.5 ns
Disease duration 18.3±13.5 17.9±12.6 ns
MMRC 134.2±13.6 136.9±15.2 ns
MMSE 27.3±1.4 27.6±1.1 ns
MMRC, megaMRC. In the DM1 population 45 patients had paternal transmission; in the DM2 population 15 patients had paternal trans-
mission. See text for details
(±14.0) on final assessment (Z=3.31, p<0.01). A significant
decrease in muscle strength (MMRC) was also observed in
DM2 over time (141.8±14.4 initially vs. 139.4±14.0 on
final assessment, Z=2.93, p<0.01). We then calculated, for
each patient, the MMRC decline per year dividing the total
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MMRC decline for the follow-up time. Average values of
MMRC decline per year were compared between groups
using the Mann–Whitney U-test. DM1 patients showed a
significantly greater MMRC decline per year (–1.23±1.43)
than DM2 patients (–0.26±0.19) (Z=–1.95, p=0.05).
We further performed an ANCOVA (adjusted for age,
education, duration of disease, years of follow-up) on the
amount of MMRC decrease as dependent variable (MMRC
at follow-up minus initial MMRC) for DM1 and for DM2.
Over time, decline in muscle strength for DM1 was signifi-
cantly greater than for DM2 (F(1, 28)=7.93, p<0.05). See
Figure 2 for details.
Neuropsychological evaluation
Initial assessment (37 DM1 and 17 DM2)
In agreement with our previous findings [19, 20], patients
with DM1 and DM2 showed an impairment in tests mea-
suring frontal function (alertness with and without warning
signal, divided attention and the Tower of London Test) and
showed an impairment of visual-spatial recall (Rey Recall)
and visual-spatial construction (Rey copy). Nonparametric
comparison showed no significant difference between DM1
V. Sansone et al.: Cognitive impairment in myotonic dystrophies
Fig. 2 Muscle strength at initial and follow-up examination in
DM1 and DM2 study population. On the y axis: mean MMRC
values; standard errors are indicated on the bar charts. MMRC
significantly decreased over time for both groups (*), but muscle
strength for DM1 patients decreased greater than DM2 (see text
for further details)
Table 2 Initial and final neuropsychological test results in 14 DM1 patients of the follow-up study population
Initial evaluation Follow-up p values
Raw score Raw score
Mean SD Mean SD
Screening test for dementia
MMSE (cut-off: 24) 27.43 1.74 28.07 1.59 ns
Nonverbal reasoning
CPM Raven (cut-off: 18) 27.77 4.3 25.50 5.63 ns
Language
Token test (cut-off: 26.5) 35.83 0.39 32.93 1.71 <0.01#
Controlled association letters test (cut-off: 17) 34.64 11.58 32.21 11.04 ns
Controlled association categories test (cut-off: 25) 42.79 7.08 3936 8.26 ns
Memory
Digit Span (cut-off: 3.75) 5.15 0.55 5.54 0.97 ns
Spatial Span (cut-off: 3.75) 4.92 0.76 4.86 1.03 ns
Story Recall (cut-off: 8) 10.46 3.26 15.46 3.27 <0.01#
Rey Recall figure (cut-off: 9.47) 12.69 7.43 15.14 7.97 ns
Constructional abilities
Rey Copy figure (cut-off: 28.88) 29.29 8.7 28.57 8.59 ns
Attentional and executive functions
Trial Making test A (cut-off: 93) 49.43 22.45 56.07 28.43 ns
Trial Making test B (cut-off: 282) 113.43 68.7 191.07 207.77 <0.01
Trial Making test B-A (cut-off: 186) 64.00 49.42 135.00 182.22 <0.01
Alertness without auditory warning signal (TEA) (ms) 228.77 21.64 264.89 37.95 <0.05
Alertness with auditory warning signal (TEA) (ms) 228.53 29.99 260.11 42.38 <0.05
Divided attention (TEA) (ms) 704.41 83.29 768.71 154.69 ns
Omission (divided attention) (TEA) 4.79 5.15 5.21 4.28 ns
Tower of London test (TOL) (%) 94.14 82.56 80.82 40.89 ns
#p value <0.05 but within normal range. Available cut-off values are indicated in brackets. For TEA and Tower of London Test where no cut-
off is available, baseline and follow-up results are used to determine improvement or worsening
and DM2 except for alertness with auditory warning signal
(TEA). Reaction time was 246±40.5 ms for DM1 compared
to 219.9±12.5 ms for DM2 (Z=–2.52, p<0.05). ANCOVA
adjusted for age, education and disease duration confirmed
the same results.
Follow-up assessment (14 DM1 and 11 DM2)
In DM1, nonparametric intra-group comparisons showed
significant worsening over time for alertness without audi-
tory warning signal (Z=2.40, p<0.05), alertness with audito-
ry warning signal (Z=2.16, p<0.05), TMT B (Z=2.92,
p<0.01) and TMT B-A (Z=3.11, p<0.01). A statistically sig-
nificant worsening was also found for the Token Test
(Z=3.48, p<0.01), while a significant improvement was
found for Story recall (Z=2.94, p<0.01). Despite the changes
described over time for these two tests [32], the scores were
within normal ranges in initial and final assessments, and
therefore clinically irrelevant. For details see Table 2.
In DM2 patients, a statistically significant worsening in
test scores over time was found for: TMT B (Z=2.76,
p<0.01) and TMT B-A (Z=2.76, p<0.01). A statistically
significant worsening was also found for the Token test
(Z=2.50, p<0.05) while a significant improvement in test
scores was found for the spatial span test (Z=2.26, p<0.05).
As in DM1, despite the changes described over time for the
Token test, the score was within normal ranges in initial
and final assessments, and therefore clinically irrelevant.
For details see Table 3.
Discussion
Follow-up studies of muscle strength [27] and cardiac
involvement [28] in DM1 have demonstrated the progres-
sion of the disease over time and have provided important
clinical information on the most frequent causes of mor-
bidity and mortality [27] in patients with this disorder.
Regarding brain involvement, so far there has been no clear
demonstration of the clinical relevance of the abnormal
neuropsychological test scores and neuroimaging findings
in patients with DM1. Longitudinal studies in cognitive
function in adult DM1 are still limited [29, 30, 33] and con-
troversial. The progressive decline in working capacity and
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Table 3 Initial and final neuropsychological test results in 11 DM2 patients of the follow-up study population
Initial evaluation Follow-up p values
Raw score Raw score
Mean SD Mean SD
Screening test for dementia
MMSE (cut-off: 24) 28.36 1.80 29.00 1.00 ns
Nonverbal reasoning
CPM Raven (cut-off: 18) 30.55 3.01 30.09 4.30 ns
Language
Token test (cut-off: 26.5) 35.30 1.34 33.23 2.33 <0.05#
Controlled association letters test (cut-off: 17) 32.00 7.29 31.00 8.01 ns
Controlled association categories test (cut-off: 25) 39.73 7.95 38.64 8.15 ns
Memory
Digit Span (cut-off: 3.75) 5.45 0.52 5.44 0.73 ns
Spatial Span (cut-off: 3.75) 4.64 0.67 5.45 0.93 <0.05#
Story Recall (cut-off: 8) 11.95 4.30 13.05 3.49 ns
Rey Recall figure (cut-off: 9.47) 15.18 7.28 15.36 6.07 ns
Constructional abilities
Rey Copy figure 
(Cut-off: 28.88) 31.68 4.58 33.36 2.98 ns
Attentional and executive functions
Trial Making test A (cut-off: 93) 54.60 22.40 52.00 19.41 ns
Trial Making test B (cut-off: 282) 107.90 30.93 178.50 71.04 <0.01
Trial Making test B-A (cut-off: 186) 53.30 17.52 126.50 61.51 <0.01
Alertness without auditory warning signal (TEA) (ms) 227.00 28.68 254.35 56.40 ns
Alertness with auditory warning signal (TEA) (ms) 218.61 13.54 249.80 89.05 ns
Divided attention (TEA) (ms) 704.72 79.16 753.90 46.78 ns
Omission (divided attention) (TEA) 3.56 2.07 4.00 2.11 ns
Tower of London test (TOL) (%) 73.22 45.06 45.53 27.49 ns
#p value <0.05 but within normal range. Available cut-off values are indicated in brackets. For TEA and Tower of London Test where no cut-
off is available, baseline and follow-up results are used to determine improvement or worsening
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physical activity in patients with DM1 has in general been
attributed to the progression of muscular symptoms and
respiratory insufficiency [34, 35]. Very limited informa-
tion, mainly on muscle strength and cardiac conduction
disturbances, is as yet available as natural history data of
patients with DM2 [19].
To our knowledge this is the first longitudinal study of
patients with DM2 that provides natural history data on
muscle and brain disease. The study is limited by the rela-
tively small number of patients available for follow-up. We
cannot rule out that a number of patients who refused fol-
low-up did so because they felt they had cognitively deteri-
orated. If so, however, the remaining sample, although
small, would underestimate cognitive decline observed over
time in our sample population. We can also state the reasons
for drop-out (18 out of 56 refusals for DM1: 32%, and 8 out
of 29: 28% refusals for DM2). We emphasise the reluctance
of these patients to perform regular out-patient follow-up
neurology visits, in agreement with the behavioural abnor-
malities previously demonstrated in these patients [19, 24].
Although based on a small number of patients, our data
confirm selective progressive frontal lobe function (atten-
tional) involvement and demonstrate that, over time, there
is no progression to additional areas of cognition, and
there is no progressive interference in ADL as in patients
with dementia associated with other medical conditions.
Interestingly, the involvement of frontal, temporal and
parietal cortical areas is in agreement with neuropatholog-
ical and biomolecular data [16, 18], demonstrating
expanded CUG and CCUG repeats by FISH in these same
areas, suggesting that CNS symptoms in DM1 and DM2
are triggered by RNA inclusions, having a deleterious
gain-of-function. In contrast to the extent and progression
of CNS involvement in other expansion disorders like
Huntington’s disease, the clinical picture of myotonic dys-
trophies, although including specific brain areas, is pre-
dominantly one of muscle involvement. We may speculate
that this may be related to the fact that in myotonic dys-
trophy patients, splicing abnormalities are less frequent
and severe in the cerebral cortex than in skeletal muscle; in
contrast a diffuse neuronal dysfunction related to the dif-
fusion of polyglutamine proteins is observed in
Huntington’s disease. This less unexpectedly gives rise to
the typical cognitive and behavioural abnormalities that
characterise patients with Huntington’s disease.
Our results also demonstrate that, over time, muscle
strength progresses in both DM1 and in DM2, but with a
faster rate in DM1 as compared to DM2, irrespective of
age, disease duration and years of follow-up. The slower
progression of muscle weakness in DM2 suggests a more
favourable prognosis for patients with DM2, although cau-
tion is needed in interpreting these results because they are
only representative of a small group of patients with DM2.
There was no correlation between the neuropsychological
test scores considered and the degree of muscle weakness.
Conclusions
We can conclude that adult myotonic dystrophies, and
specifically DM2, like DM1, although to a minor degree,
are progressive muscle disorders. From a cognitive point of
view these disorders are also characterised by specific and
progressive frontal cognitive impairment (attentional),
without extension to additional areas of cognition. The
awareness of cognitive and behavioural symptoms,
although not progressive, may help to understand why
patients with DM1 and DM2 may not function as well in
their work-related and family-related activities as expected
by their muscle disability. When muscle strength is
impaired, as in patients with DM1 and DM2, the efficacy
of a specific treatment whose target is muscle strength
improvement, may be underestimated by the coexistence
of a dysexecutive syndrome. We recommend that both
aspects of muscle and CNS involvement should be consid-
ered when planning a clinical trial.
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